Germany reports

Germany is the inverse of most markets. A newly licensed medicine is reimbursed from launch, and the price is negotiated after a benefit assessment. That gives immediate revenue and immediate exposure: the assessment determines the negotiated price that follows, and the finding is what a manufacturer defends.

The assessment turns on demonstrated additional benefit against an appropriate comparator. Orphan medicines follow a modified route in which additional benefit is accepted by virtue of the authorisation, which is a materially easier position than arguing the case through a full dossier. An asset without that standing has to win the finding the hard way.

Because Germany's prices are visible and widely referenced by other countries, the outcome does not stay in Germany. A weak finding here propagates through international reference-pricing baskets across Europe.

AXLRx Germany reports cover the route an asset should expect, the comparator it will be assessed against, the precedent set by agents already through the process, and the reference-pricing exposure the resulting price creates elsewhere.